A Randomized, Double-blind, Placebo-controlled Study of Efficacy, Safety and Tolerability of Secukinumab at 12 Weeks Administered With an Intravenous (i.v.) or Subcutaneous (s.c.) Loading Regimen Compared to Placebo in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
收藏DataCite Commons2026-03-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012923/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study compared the efficacy and assessed the safety of secukinumab given as 3 intravenous (i.v.) loading doses or weekly sub-cutaneous (s.c.) loading doses, compared to placebo, followed by monthly s.c. injections in patients with active Rheumatoid Arthritis (RA) despite treatment with Methotrexate.
提供机构：
Vivli
创建时间：
2026-03-27
